-transparent.png){kind=logo}
The vascular and steroidogenic responses to (1-Sarcosine, 8-Isoleucine)-, and to (1-Des (Aspartic acid), 8-Isoleucine) angiotensin II were compared in bilaterally nephrectomized, ACTH-suppressed dogs receiving constant infusions of angiotensin II. Aldosterone secretion rate was significantly inhibited by pretreatment with 200 ng/Kg/min of the heptapeptide, (1-Des(Aspartic acid), 8-Isoleucine) ang II, but not by similar doses of the octapeptide, (1-Sarcosine, 8-Isoleucine) ang II. In contrast, the pressor action of ang II was unaffected by (1-Des (Aspartic acid), 8-Isoleucine) ang II though significant inhibition occurred with relatively small doses of (1-Sarcosine, 8-Isoleucine) ang II. This study suggests that: (a) angiotensin receptors in adrenal cortex and vascular smooth muscle are functionally different, and (b) (1-Des(Aspartic acid),8-Isoleucine) angiotensin II is a specific antagonist of steroidogenic effect of ang II.
E L Bravo, and
M C Khosla, and
F M Bumpus
January 1973,
Journal of medicinal chemistry,
E L Bravo, and
M C Khosla, and
F M Bumpus
August 1977,
Japanese circulation journal,
E L Bravo, and
M C Khosla, and
F M Bumpus
July 1978,
Research communications in chemical pathology and pharmacology,
E L Bravo, and
M C Khosla, and
F M Bumpus
February 1977,
Journal of medicinal chemistry,
E L Bravo, and
M C Khosla, and
F M Bumpus
April 1966,
Biochemistry,
E L Bravo, and
M C Khosla, and
F M Bumpus
June 1974,
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
E L Bravo, and
M C Khosla, and
F M Bumpus
December 1978,
Clinical science and molecular medicine. Supplement,
E L Bravo, and
M C Khosla, and
F M Bumpus
April 1973,
The Journal of pharmacology and experimental therapeutics,
E L Bravo, and
M C Khosla, and
F M Bumpus
June 1975,
Circulation research,
E L Bravo, and
M C Khosla, and
F M Bumpus
March 1975,
Horumon to rinsho. Clinical endocrinology,
